Clinical trial
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous…
NCT00130702 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00130702 |
|---|---|
| Title | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia |
| Official title | A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Boston Children's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelogenous Leukemia, Acute |
| Intervention type | Drug |
| Interventions | gefitinib |
| Enrollment | 18 |
| Start date | Aug 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Aug 16, 2005 |
| Last update posted | May 1, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: